Every Form 4 that Gain Therapeutics, Inc. (GANX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GANX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GANX filings page.
Gain Therapeutics, Inc. granted director GOLDSTEIN DOV A MD a stock option covering 25,000 shares of common stock at an exercise price of $1.68 per share. The option vests in 12 equal monthly installments beginning July 24, 2026, subject to his continuous service, and expires on July 15, 2036. Following this grant, he holds options on 25,000 shares.
Gain Therapeutics director Claude Nicaise received a grant of stock options covering 25,000 shares of common stock at an exercise price of $1.68 per share. The options expire on July 15, 2036 and vest in 12 equal monthly installments starting July 24, 2026, subject to his continuous service, resulting in 25,000 options held directly after the grant.
Gain Therapeutics director Khalid Islam reported a grant of stock options for 25,000 shares of common stock on July 15, 2026. The options carry a $1.6800 exercise price, expire on July 15, 2036, and vest in 12 equal monthly installments starting July 24, 2026, contingent on his continuous service.
Gain Therapeutics, Inc. reported that director Gwen A. Melincoff received a grant of stock options covering 25,000 shares of Common Stock on 2026-07-15. The options have an exercise price of $1.68 per share, expire on 2036-07-15, and result in direct ownership of 25,000 derivative securities.
According to the grant terms, the option vests in 12 equal monthly installments starting on July 24, 2026, subject to Melincoff’s continuous service through each applicable vesting date.
Gain Therapeutics director Jeffrey Scott Riley received a grant of stock options for 25,000 shares of common stock on July 15, 2026. The options have a $1.68 exercise price and expire on July 15, 2036. They vest in 12 equal monthly installments starting July 24, 2026, contingent on his continuous service, resulting in 25,000 options held directly after the grant.
Gain Therapeutics, Inc. reported that director Hans Peter Hasler received a grant of 25,000 stock options on 2026-07-15. The options have an exercise price of $1.68 per share for Gain Therapeutics common stock and expire on 2036-07-15. They vest in 12 equal monthly installments commencing on July 24, 2026, conditioned on his continuous service through each vesting date. Following this award, he directly holds 25,000 derivative securities linked to common stock. The filing indicates the transaction was not made under a Rule 10b5-1 trading plan.
Gain Therapeutics, Inc. reported that CEO and President Gene Mack received a grant of 200,000 employee stock options to buy common stock at an exercise price of $1.86 per share. All 200,000 options were newly awarded and represent his total option holdings reported after this grant.
The options expire on March 24, 2036. According to the vesting terms, 25% of the underlying shares vest on March 24, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, as long as he continues in service through each vesting date.
Gain Therapeutics, Inc. reported that officer Gianluca Fuggetta received a grant of employee stock options covering 50,000 shares of common stock. The options have an exercise price of $1.86 per share and expire on March 24, 2036.
These options were awarded as a compensation-related grant, not an open-market purchase. According to the vesting terms, 25% of the underlying shares vest on March 24, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, as long as he remains in continuous service. Following this grant, he holds 50,000 options directly.